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Abstract
Cystic fibrosis (CF) is caused by mutations in the CF transmembrane regulator (CFTR) that result 
in reduced anion conductance at the apical membrane of secretory epithelia. Treatment of CF 
patients carrying the G551D gating mutation with the potentiator VX-770 (ivacaftor) largely 
restores channel activity and has shown substantial clinical benefit. However, most CF patients 
carry the ΔF508 mutation, which impairs CFTR folding, processing, function, and stability. 
Studies in homozygous ΔF508 CF patients indicated little clinical benefit of monotherapy with the 
investigational corrector VX-809 (lumacaftor) or VX-770, whereas combination clinical trials 
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show limited but significant improvements in lung function. We show that VX-770, as well as 
most other potentiators, reduces the correction efficacy of VX-809 and another investigational 
corrector, VX-661. To mimic the administration of VX-770 alone or in combination with VX-809, 
we examined its long-term effect in immortalized and primary human respiratory epithelia. 
VX-770 diminished the folding efficiency and the metabolic stability of ΔF508-CFTR at the 
endoplasmic reticulum (ER) and post-ER compartments, respectively, causing reduced cell 
surface ΔF508-CFTR density and function. VX-770–induced destabilization of ΔF508-CFTR was 
influenced by second-site suppressor mutations of the folding defect and was prevented by 
stabilization of the nucleotide-binding domain 1 (NBD1)–NBD2 interface. The reduced correction 
efficiency of ΔF508-CFTR, as well as of two other processing mutations in the presence of 
VX-770, suggests the need for further optimization of potentiators to maximize the clinical benefit 
of corrector-potentiator combination therapy in CF.
INTRODUCTION
Cystic fibrosis (CF), one of the most common inherited diseases in the Caucasian 
population, is caused by mutations in the CF transmembrane regulator (CFTR) gene that 
lead to loss of CFTR channel function and impaired epithelial anion transport in the lung, 
intestine, pancreas, and other organs (1, 2). The nearly 2000 different mutations identified in 
the CFTR gene (http://www.genet.sickkids.on.ca) have been categorized into six different 
classes according to the resulting molecular aberration (3, 4). The most prevalent class II 
mutation, deletion of phenylalanine 508 (ΔF508), results in misfolded CFTR channels that 
are predominantly recognized and degraded by the endoplasmic reticulum (ER) quality 
control machinery (2, 5). ΔF508-CFTR molecules that escape from the ER are functionally 
impaired (class III mutation) and conformationally unstable, with rapid removal from the 
plasma membrane (PM) by the peripheral quality control and targeting for endolysosomal 
degradation (6). G551D, the third most common CF-causing mutation that affects ~4% of 
CF patients, belongs to class III and displays normal processing and cell surface expression 
but severe functional impairment (7).
The CFTR protein is an ATP (adenosine 5′-triphosphate)–binding cassette transporter family 
member that comprises two membrane-spanning domains (MSD1 and MSD2) and three 
cytosolic domains, two nucleotide-binding domains (NBD1 and NBD2) and a regulatory 
domain (8). The ΔF508 mutation in the NBD1 produces multiple structural defects in CFTR. 
At least two of those, NBD1 misfolding and NBD1-MSD1/2 interfacial instability, have to 
be reversed genetically and/or pharmacologically to achieve near wild type–like PM 
expression (9–13).
Mechanistically, the available investigational small-molecule CFTR modulators fall into 
three classes: (i) suppressor molecules that prevent premature termination of protein 
synthesis; (ii) correctors that partially revert the folding and processing defects; and (iii) 
potentiators that increase channel gating and conductance (14–16). The potentiator ivacaftor 
(VX-770, Kalydeco) has been approved for therapy of CF patients with one copy of G551D 
(17) or some other rare gating mutations (18, 19). VX-770 treatment of patients with G551D 
and other class III mutations demonstrated marked clinical benefit, including ~10 to 14% 
Veit et al. Page 2
Sci Transl Med. Author manuscript; available in PMC 2015 July 23.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
increase in the forced expiratory volume in 1 s (FEV1), decrease in pulmonary 
exacerbations, and weight gain relative to placebo treatment (20–22).
Nasal potential difference and short-circuit current (Isc) measurements in rectal biopsies of 
CF patients as well as in primary human bronchial epithelial (HBE) cells indicate that a 
subset of homozygous ΔF508 patients have residual ΔF508-CFTR PM function (23–25). 
The PM expression and activity of ΔF508-CFTR inversely correlate with CF disease 
severity (23, 25, 26). Acute addition of VX-770 in HBE cell cultures from some patients 
homozygous for the ΔF508 mutation increased the residual forskolin-stimulated channel 
activity from ~4 to 16% of that in HBE cultures from non-CF individuals, whereas other 
cultures were not responsive (24). A phase 2 trial in ΔF508 homozygous patients, however, 
showed no improvement in FEV1, although a small reduction in sweat chloride 
concentration upon VX-770 treatment occurred (27).
Likewise, treatment with VX-809 (lumacaftor) alone, a promising investigational corrector 
drug that restores the ΔF508-CFTR PM expression and function to ~15% of wild-type 
CFTR activity in non-CF HBE cells (28), failed to show robust improvement in lung 
function of ΔF508/ΔF508 patients (29). In cell cultures, a combination of chronic VX-809 
and acute VX-770, together with a cAMP (cyclic adenosine 3′,5′-monophosphate) agonist, 
increased ΔF508-CFTR conductance to ~25% of that in non-CF HBE (28). These preclinical 
results motivated the ongoing phase 2–3 clinical trials of combination treatment with 
VX-770 and VX-809, or VX-661, another investigational corrector (14) (http://
www.clinicaltrials.gov NCT01225211 and NCT01531673). The results of a phase 2 trial in 
homozygous ΔF508 patients receiving VX-809 and VX-770 combination treatment 
suggested an improvement in FEV1 of 8.6% compared to placebo (P < 0.001) and amarginal 
decrease in sweat chloride concentration (30), although sustained clinical benefit awaits 
verification. The recent news release of the first phase 3 trials reported a mean absolute 
improvement in FEV1 compared to placebo in the range of 2.6 to 4.0% (P ≤0.0004) (31). 
The limited clinical efficacy of combination therapy based on these data may be accounted 
for by insufficient tissue concentration of the drugs, decreased susceptibility to correction in 
the inflamed lung, and/or conformational destabilization of the mutant upon chronic 
exposure to VX-770. To evaluate the latter possibility, we determined the effect of 
prolonged exposure to VX-770, and to other investigational potentiators, on the biochemical 
and functional expression of ΔF508-CFTR. The results indicate that VX-770 and some, but 
not all, other potentiators cause ΔF508-CFTR destabilization at multiple cellular sites in 
model systems and primary CF HBE, with consequent reduced functional expression of 
ΔF508-CFTR at the cell surface.
RESULTS
Prolonged exposure to VX-770 reduces the PM and cellular expression of ΔF508-CFTR
To investigate the effect of prolonged exposure to VX-770 on ΔF508-CFTR PM expression, 
we first used the human CF bronchial epithelial cell line CFBE41o− (referred to as CFBE), a 
widely validated model system with CFTRΔF508/ΔF508 genetic background but no detectable 
CFTR protein expression (32). CFBE cells were engineered for inducible expression of 
CFTR variants as described (10, 33). To facilitate the PM detection of ΔF508-CFTR, 
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horseradish peroxidase isoenzyme C (HRP-C) was genetically engineered into its fourth 
extracellular loop. The functional and biochemical properties of ΔF508-CFTR-HRP are 
similar to those of the 3HA-tagged variant (13, 34) (fig. S1, A to D).
Acute addition of VX-770 to low temperature–rescued ΔF508-CFTR (rΔF508) in CFBE 
cells increased the cAMP-dependent protein kinase (PKA)–activated current by up to sixfold 
with EC50 of 12.8 ± 1.0 nM (fig. S2, A and B), similar to that reported in ΔF508/ΔF508 
HBE cells (22 ± 10 nM) (24). Prolonged exposure (24 hours) to VX-770, however, caused a 
concentration-dependent decrease in the PM density of ΔF508-CFTR, regardless of whether 
the preincubation with VX-770 was done at physiological temperature or at 26 to 30°C, 
which facilitated ΔF508 CFTR biosynthetic processing (Fig. 1, A and B). The maximal 
reduction in ΔF508-CFTR PM density was attained at ~30 nM VX-770, well below the 
plasma concentration of ~3.5 µM in VX-770–treated CF patients (35). Although increasing 
the concentration of human serum (0 to 100%) raised the EC50 of VX-770 from 2.5 ± 0.2 
nM to 23.1 ± 4.6 nM in the presence of VX-809, it did not affect the reduced PM density 
achieved by long-term treatment with ≥100 nM VX-770 (fig. S2, G and H). In contrast, the 
PM density of wild-type CFTR or G551D-CFTR was not reduced by prolonged VX-770 
exposure (Fig. 1, A and C).
VX-809 partially restored ΔF508-CFTR biogenesis, function, and PM expression by about 
three- to fourfold in CFBE and primary HBE monolayers (fig. S2C) (10, 13, 28). VX-809 
alone or in combination with low-temperature rescue, however, failed to prevent the 
VX-770–dependent reduction in ΔF508-CFTR PM density (Fig. 1, A and B, and fig. S2C). 
Similar results were obtained for ΔF508-CFTR rescued with the corrector VX-661 (fig. 
S2D). The VX-770–induced reduction in ΔF508-CFTR PM density was independent of 
channel gating because neither activation of adenyl cyclase by forskolin nor blocking the 
channel with BPO-27 (36) influenced the VX-770 effect (Fig. 1B and fig. S2C). Extended 
exposure to VX-770 did not affect cell viability (fig. S2E). PM down-regulation of 3HA-
tagged ΔF508-CFTR by VX-770 in low temperature–rescued CFBE, NCI-H441 (a lung 
adenocarcinoma cell line exhibiting some Clara cell features), and MDCK II (Madin-Darby 
canine kidney) epithelial cells suggested that the VX-770 effect is not CFBE-specific or 
related to the HRP-tag insertion (Fig. 1D and fig. S2F).
To evaluate whether VX-770 causes the redistribution of PM resident ΔF508-CFTR to 
intracellular pools or exerts a global down-regulation of mature ΔF508-CFTR in post-ER 
compartments, we determined the cellular expression of ΔF508-CFTR by immunoblot 
analysis. VX-770 treatment for 24 hours decreased the amount of the complex-glycosylated 
ΔF508-CFTR (C-band) in CFBE lysates in a dose-dependent manner (Fig. 1E). The VX-770 
effect was attenuated in VX-809– or VX-661–treated cells, probably due to partial 
stabilization of the mature ΔF508-CFTR pool by VX-809, as reported previously (Fig. 1, F 
and G) (10, 28, 37). In contrast, the complex-glycosylated form of wild-type CFTR and 
G551D-CFTR was not affected by prolonged VX-770 exposure (Fig. 1H). The modest, 
albeit significant (P = 0.02), decrease in the steady-state level of core-glycosylated ΔF508-
CFTR (B-band) may be due to reduced biogenesis and/or accelerated ER degradation upon 
exposure to 100 nM VX-770 (Fig. 1, E to G). These observations suggest that the VX-770 
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effect cannot be explained merely by accelerated internalization or impeded recycling of 
rΔF508-CFTR.
ΔF508-CFTR chloride conductance decreases after long-term VX-770 exposure in CFBE 
and primary respiratory epithelia
To assess the functional consequence of prolonged VX-770 exposure of CFBE and primary 
HBE cells, we performed short-circuit current (Isc) measurements after 24 hours of 
incubation with 100 nM VX-770. Forskolin-stimulated Isc was measured after inhibition of 
ENaC (epithelial sodium channel) by amiloride and maximal acute potentiation of cell 
surface ΔF508-CFTR function with 10 µM VX-770 (Fig. 2A). Forskolin-stimulated Isc (1.7 
± 0.3 µA/cm2) was reduced to 1.1 ± 0.2 µA/cm after incubation of ΔF508-CFTR–expressing 
CFBE cells with VX-770 for 24 hours. A comparable reduction in Isc was observed in 
VX-809– and VX-661–corrected cells (Fig. 2, A and B).
To confirm the relevance of these results to human tissues, we assessed the VX-770 effect in 
primary HBE cell cultures, isolated from the lungs of six CFTRΔF508/ΔF508 patients and four 
CFTRWT/WT donors. The HBE cells were differentiated on Snapwell filter inserts under air-
liquid interface (ALI) conditions for at least 4 weeks either in Ultroser G medium (i), which 
increases the ENaC- and CFTR-mediated currents (38), or in ALI medium (ii) (39) (Fig. 2, 
C and D). The residual CFTR-mediated Isc in the ΔF508-CFTR HBE was augmented by 
treatment with the correctors VX-809 or VX-661 (3 µM, 24 hours) (13). To further increase 
CFTR-mediated Isc and isolate the apical anion conductance, some cells were differentiated 
in Ultroser G medium and analyzed after basolateral permeabilization and in the presence of 
a basolateral-to-apical Cl− gradient. Independent of the differentiation method and presence 
of a chloride gradient, exposure to VX-770 for 24 hours decreased the VX-809– or VX-661–
corrected ΔF508-CFTR current by 33 ± 6% and 47 ± 8% (mean ± SEM, n = 6), respectively 
(Fig. 2, C and D, and Table 1). In contrast, VX-770 pretreatment did not affect the PKA-
activated wild-type CFTR current in HBE (Fig. 2E and table S1), in line with the absence of 
changes in PM and C-band density in wild-type CFTR (Fig. 1H).
Potentiator P5 does not impair the PM density and function of ΔF508-CFTR
To determine whether down-regulation of rΔF508-CFTR is a universal phenomenon of 
long-term potentiator exposure, we tested a panel of CFTR potentiators with distinct 
chemical structures. These investigational small molecules, abbreviated as P1 to P10, were 
made available by the Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) for the research 
community (fig. S3A). The potency and efficacy of P1 to P10 on the activity of low-
temperature rΔF508-CFTR were demonstrated in CFBE cells using the halide-sensitive 
yellow fluorescent protein (YFP) quenching assay. Acute addition of P1 to P8 confirmed the 
potentiation of the rΔF508-CFTR activity, whereas P9 and P10 had only small effects (Fig. 
3, A to H, and fig. S3, B to D). The dose-response curve of genistein (P6), a flavone widely 
used for acute potentiation of CFTR activity, did not reach saturation activity at 100 µM, 
suggesting that rΔF508-CFTR has lower affinity for genistein than wild-type CFTR (40, 41) 
(Fig. 3F).
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Prolonged treatment (24 hours) with most potentiators produced a concentration-dependent 
decrease in ΔF508-CFTR PM density in CFBE partially rescued with low temperature alone 
or in combination with VX-809 (Fig. 3, A to H). This was especially prominent for genistein 
(P6), with ~60 and ~75% decrease in rΔF508-CFTR PM density and conductance, 
respectively (Fig. 3, F, I, and J). P5 did not reduce the ΔF508-CFTR PM density and 
potentiated the rΔF508-CFTR activity by up to about sevenfold in CFBE cells (Fig. 3E). 
This result was confirmed by immunoblot analysis of low-temperature and VX-809 rΔF508-
CFTR. Increasing concentrations of P5 did not alter the relative abundance of core- and 
complex-glycosylated ΔF508-CFTR, suggesting that P5 does not affect ΔF508-CFTR ER 
processing and stability (Fig. 4A).
Isc measurements in CFBE expressing ΔF508-CFTR and primary HBE cells isolated from 
four CFTRΔF508/ΔF508 patients also confirmed the lack of effect of prolonged P5 exposure 
on the maximal activation of ΔF508-CFTR current at physiological temperature (Fig. 4, B 
and C, and Table 1). P5 may thus be a useful investigational compound to potentiate ΔF508-
CFTR function without impairing its PM expression.
VX-770 impairs biogenesis, stability, and endocytic trafficking of the ΔF508-CFTR
Because VX-770 may impair both the biogenesis and the metabolic stability of mature 
ΔF508-CFTR, according to the immunoblot analysis, we measured conformational 
maturation of newly formed ΔF508 CFTR by the metabolic pulse-chase technique (11). 
Phosphorimage analysis was used to quantify the conversion efficiency of core-glycosylated 
ΔF508-CFTR (B-band), labeled with [35S]methionine and [35S]cysteine, into complex-
glycosylated ΔF508-CFTR (C-band) upon traversing the cis/medial Golgi in CFBE cells. 
The folding efficiency of ΔF508-CFTR in the presence of VX-809 decreased from 1.8 ± 
0.2% to 1.3 ± 0.1% after VX-770 treatment for 24 hours, representing a ~25% (P = 0.026) 
reduction (Fig. 5A, left panel). Similarly, the folding efficiency of VX-770–treated ΔF508-
CFTR-3S, carrying NBD1-stabilizing second-site mutations, decreased from 4.0 ± 0.2% to 
2.6 ± 0.6% (P = 0.049) (Fig. 5A, right panel). The reduced ER maturation efficiency cannot 
be attributed to decreased transcription or profoundly increased degradation of the core-
glycosylated ΔF508-CFTR because neither the mRNA level nor the B-band stability was 
affected by VX-770 (fig. S4, A to C). The decreased incorporation of radioactivity during 
the 30-min pulse is consistent with increased cotranslational degradation and/or partial 
translational inhibition (fig. S4D).
The peripheral stability of rΔF508-CFTR was determined both at the PM and in post-ER 
compartments in CFBE cells. After the accumulation of low temperature–rescued ΔF508-
CFTR at the PM, it was rapidly removed with a T1/2 ~2.5 hours at 37°C (Fig. 5B), probably 
as a result of accelerated internalization, lysosomal targeting, and attenuated recycling, as 
reported in HeLa cells (6). The T1/2 of rΔF508-CFTR at the PM was decreased by VX-770 
to ~1.75 hours, regardless of whether VX-770 was present for 24 or 3 hours (Fig. 5B). 
VX-770 also accelerated the PM turnover of rΔF508-CFTR that was modestly stabilized by 
VX-809 (28), as reflected by the reduction of T1/2 from ~3 to ~2.25 hours (Fig. 5C). In 
addition, VX-770 destabilized the complex-glycosylated rΔF508-CFTR pool both in the 
presence and in the absence of VX-809, as determined by cycloheximide (CHX) chase and 
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immunoblot (Fig. 5, D and E). Similar results were obtained by metabolic pulse-chase for 
rΔF508-CFTR containing the 3S NBD1 stabilizing mutation (fig. S4E). Together, these 
observations suggest that VX-770 interferes with both the biogenesis and the peripheral 
stability of mature ΔF508-CFTR in the presence or absence of VX-809, which likely 
accounts for reduced ΔF508-CFTR PM function. As found for VX-770, prolonged treatment 
with potentiators P1, P2, P4, P6, and P7 led to a destabilization of PM-localized rΔF508-
CFTR (Fig. 5F). Notably, destabilization was not seen in CFBE treated with P3 or P5 (Fig. 
5F).
The conformational destabilization of rΔF508-CFTR by VX-770 may be recognized by the 
peripheral quality control machinery that targets non-native PM proteins for lysosomal 
degradation (42). This possibility was assessed by determining the post-endocytic fate of 
rΔF508-CFTR by measuring the pH of CFTR-containing endocytic vesicles with 
fluorescence ratio image analysis (FRIA) (43). rΔF508-CFTR was accumulated in polarized, 
filter-grown CFBE at reduced temperature and exposed for 24 hours to 
DMSO,VX-809,VX-770, or VX-809 + VX-770. The rΔF508-CFTR-3HA was unfolded at 
37°C for 1.5 hours and then labeled with pH-sensitive FITC (fluorescein isothiocyanate) at 
0°C, using the antibody capture technique as described in Materials and Methods. 
Internalization of labeled PM ΔF508-CFTR was initiated by shifting the temperature to 
37°C.
Endocytosed rΔF508-CFTR was delivered after 30 min into multivesicular bodies (MVB)/
lysosomes (pH 5.25 ± 0.01), whereas wild-type CFTR largely remained in early endosomes 
(Fig. 5, G and H, and fig. S4F). MVB/lysosomal delivery was inhibited by VX-809, as seen 
by preferential confinement to early endosomes (pH 6.31 ± 0.1) during a 2-hour chase (Fig. 
5, G and H). VX-770 partially reversed the VX-809 trafficking effect by facilitating rΔF508-
CFTR transfer to late endosomes, as indicated by the pH (5.84 ± 0.1) of the rΔF508-CFTR–
containing vesicular compartment after a 2-hour chase (Fig. 5, G and H), suggesting that 
VX-770 increases ΔF508-CFTR susceptibility to recognition by the peripheral quality 
control machinery.
The effect of VX-770 at the single-molecule level was measured by determining the channel 
function of rΔF508-CFTR with or without second-site suppressor mutations in reconstituted 
planar phospholipid bilayer (Fig. 6, A to E). R29K and R555K mutations were introduced 
(ΔF508-CFTR-2RK) to increase channel reconstitution efficiency (44). The open probability 
(Po) of phosphorylated ΔF508-CFTR-2RK channel decreased from 0.19 to 0.09 upon 
increasing the temperature from 24 to 36°C (Fig. 6B). VX-770 enhanced ΔF508-CFTR-2RK 
function at low temperature (Po = 0.43 at 24°C), but accelerated its inactivation rate, as 
indicated by the ~3.5-fold faster loss of channel activity between 32 and 36°C (−18.1 ± 
1.4%/°C in the presence of VX-770 versus −4.9 ± 2.8%/°C inactivation rate in the control) 
(Fig. 6, A to C). These results suggest a direct interaction of VX-770 with ΔF508-
CFTR-2RK, resulting in its destabilization.
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Second-site mutations modulate ΔF508-CFTR susceptibility to VX-770–mediated down-
regulation
Second-site suppressor mutations in ΔF508-CFTR have been used to investigate 
mechanisms of small-molecule CFTR modulators (10) (fig. S5A). An increasing number of 
solubilizing mutations (1S, 2S, and 3S) progressively stabilize the isolated ΔF508-NBD1 
domain energetically (see table S2 for list of all mutants) (11, 45–47). Similarly, NBD1-
MSD2 interface–stabilizing mutants (for example, R1070W or V510D) (8, 48) enhance the 
PM expression of ΔF508-CFTR PM to ~5 to 10% of wild-type CFTR. Combining the two 
classes of mutations increased expression to ~50% of wild-type CFTR by aiding coupled 
domain folding (10, 11). Unexpectedly, neither solubilizing nor interface-stabilizing 
mutations alone or in combination prevented the reduction in ΔF508-CFTR expression after 
prolonged VX-770 exposure, regardless of the presence of VX-809 (Fig. 7, A and B, and 
fig. S5, B to F). Solubilizing mutations augmented the loss of ΔF508-CFTR PM expression 
by VX-770 from ~45 to ~80% and decreased the IC50 of VX-770 from ~10 nM to 1 to 2 nM 
(P = 0.0020 to 0.0153) (Fig. 7, A to C, and fig. S5, B and C). In contrast, the C-terminal 70–
amino acid truncation (Δ70 CFTR), which reduced the PM stability and expression by ~90% 
relative to wild-type CFTR (49), was resistant to prolonged VX-770 treatment (Fig. 7A and 
fig. S5G). The lack of apparent correlation between global down-regulation of ΔF508-CFTR 
PM density and the extent of VX-770–induced destabilization is further supported by the 
phenotype of revertant mutations [3R; G550E, R553Q, and R555K (50)] alone or in 
combination with 1S (R1S). These mutations energetically stabilize the ΔF508-NBD1 to an 
extent comparable to 3S, increase the PM density to ~40 to 50% of wild-type CFTR (11), 
and either directly or indirectly delay NBD1-NBD2 dimer dissociation (11, 51) and channel 
closing, manifesting in about twofold increased Po (Fig. 6D and fig. S6A). 3R or R1S 
mutations prevented the VX-770–induced down-regulation of ΔF508-CFTR from the PM 
(Fig. 7, A and D, and fig. S5H), and the R1S mutation eliminated the thermal inactivation in 
the bilayer and attenuated the potentiating effect of VX-770 (Fig. 6D and fig. S6A). 
Similarly, the ΔF508-E1371S (E1371S) mutation, which increases NBD1-NBD2 dimer 
stability by preventing the hydrolysis of bound ATP to the Walker A and B motifs in NBD2 
and thereby the dissociation of the NBD1-NBD2 dimer (52, 53), protected ΔF508-CFTR 
from thermal inactivation in reconstituted planar phospholipid bilayer experiments 
regardless of the presence of VX-770 (Fig. 6E and fig. S6B).
To offer a possible explanation for the VX-770 interaction with ΔF508-CFTR, we propose 
the formation of multiple binding pockets in the partially unfolded ΔF508-NBD1/2, based 
on molecular dynamics simulations and docking studies (fig. S7A). The putative binding 
sites of VX-770 are labeled in red in the ΔF508-CFTR structure (fig. S7B). High-
affinity/low binding energy (less than −6.5 kcal/mol) interactions of VX-770 with amino 
acids in the NBD1/2 interface and the coupling helix of CL1 in ΔF508-CFTR only partially 
overlap with those in wild-type CFTR (fig. S7C), consistent with the absence of the 
destabilizing effect of VX-770 in wild-type CFTR. The lack of VX-770 destabilizing effect 
on the revertant and NBD2 ATPase (adenosine triphosphatase) mutants is in line with the 
notion that prolonged NBD1-NBD2 dimerization (51, 54) either directly or allosterically 
hinders the VX-770 association with destabilizing sites. Although the dockings studies 
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suggest partially overlapping putative binding sites for P5 and VX-770, P5 also has unique 
interactions in NBD1 (amino acids 621 to 623) that are not observed for VX-770 (fig. S7D).
Rare CF mutations sensitize CFTR to VX-770–induced down-regulation
Gating potentiation of class III mutations by acute VX-770 exposure in preclinical settings 
rationalized the approval of ivacaftor in patients with eight rare CF mutations (19). To 
evaluate whether prolonged VX-770 exposure may interfere with the expression of other 
class III and class II mutations, we determined the PM density and function of R347H-, 
R170G-, and P67L-CFTR (fig. S8A) in CFBE. Whereas R347H-CFTR, a class III mutation 
(55), was resistant to VX-770, PM expression was reduced by 30 to 43% and forskolin-
stimulated Isc was reduced by 32 to 38% in VX-809–rescued R170G-CFTR and P67L-
CFTR by VX-770 (Fig. 7, E to H, and fig. S8, B and C), raising the possibility that multiple 
class II mutations are susceptible to VX-770–mediated destabilization.
DISCUSSION
Here, we provide evidence that basal and VX-809– or VX-661–rescued PM densities of 
ΔF508-CFTR are reduced in parallel with the loss of chloride conductance upon prolonged 
exposure to VX-770. The reduction in channel density was not prevented by partial 
correction of the ΔF508-CFTR biogenesis defect by low temperature. In contrast, the PM 
expression of wild-type CFTR and G551D-CFTR was not reduced by prolonged VX-770 
treatment.
Although the cellular basis of the destabilizing action of VX-770 on ΔF508-CFTR is well 
documented both in this work and in an accompanying publication (56), its molecular details 
remain to be elucidated. Although indirect effect cannot be ruled out, we postulate that 
direct association of VX-770 with ΔF508-CFTR increases its unfolding propensity, an 
inference supported by the accelerated rate of functional inactivation of temperature-rescued 
ΔF508-CFTR-2RK in reconstituted planar lipid bilayers. The conformational destabilization 
of ΔF508-CFTR by VX-770 is also in line with its reduced ER folding efficiency, 
accelerated PM, and post-ER pool turnover, as well as lysosomal targeting from early 
endosomes, phenomena that have been described as hallmarks of the peripheral quality 
control of non-native membrane proteins (6, 42).
Conformational stabilization of NBD1 or the NBD1-MSD2 interface with second-site 
mutations (1S, 2S, or 3S and R1070W or V510D, respectively) sensitized ΔF508-CFTR to 
VX-770, as reflected by the increased fractional down-regulation and decreased IC50 (from 
~10 to ~2 nM) despite partial rescue of misprocessing of these mutant variants (11). Despite 
conferring similar energetic stabilization as NBD1-3S, the revertant mutations that are 
clustered at residues 550 to 555 (11) bestowed complete resistance to PM down-regulation 
and thermal functional inactivation in the bilayer by VX-770. Because the revertant 
mutations probably stabilize the NBD1-NBD2 dimer (51), this observation suggests that an 
unstable NBD1-NBD2 interface is a prerequisite for the VX-770 destabilizing action, an 
inference that is supported by the resistance of ΔF508-CFTR-E1371S to VX-770. The 
E1371S substitution retards channel closing by preventing the hydrolysis of bound ATP to 
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the Walker A and B motifs in NBD2 and thereby the dissociation of the NBD1-NBD2 dimer 
(52, 53).
Monotherapy with VX-809, which increased ΔF508-CFTR–mediated Isc to ~14% of that in 
wild-type CFTR in primary HBE (28), did not confer substantial clinical benefit (29). The 
maximally stimulated Isc in VX-809–rescued ΔF508/ΔF508-HBE in combination with acute 
VX-770 potentiation reached ~23% of that in non-CF HBE in our studies (Table 1 and table 
S1). These results are consistent with published data suggesting an Isc equivalent to ~25% of 
that in non-CFHBE (twofold increase over VX-809 alone) (28). Prolonged VX-770 
exposure reduced the ΔF508 Isc by 33 ± 6% (mean ± SEM, n = 6) in VX-809–corrected 
HBE, albeit with a considerable range of values in cells from different CF patients (12 to 
49%, Table 1), which is likely due to the influence of the genetic or epigenetic variability 
between individuals on the proteostasis network activity (57, 58). In VX-661–rescued 
ΔF508/ΔF508-HBE, the VX-770–induced functional attenuation ranged between 14 and 
65% with a mean of 47 ± 8% (± SEM, n = 6) (Table 1). If these results translate to the 
clinical setting, combination of corrector therapy with VX-770 could be beneficial for a 
subpopulation of ΔF508 CF patients, but may reduce the overall rescue efficiency below the 
threshold required for clinical benefit in poor VX-809 responders and/or individuals 
susceptible to VX-770–mediated channel destabilization. The negative action of VX-770 
would be more pronounced in patients having a single copy of ΔF508-CFTR.
A limitation of our study is that the concentration of free VX-770 in lung cells of CF 
patients treated with VX-770 is not known, and hence, the VX-770–induced down-
regulation of ΔF508-CFTR can only be extrapolated. VX-770 treatment with the 
recommended dose of 150 mg every 12 hours produced a peak plasma concentration of 3.5 
µM after 5 days (35). Because ~97% of VX-770 is bound to plasma protein (35, 59), the free 
drug concentration is estimated to be ~100 nM in vivo, which is in line with its clinical 
benefit in patients carrying at least one G551D allele (21, 22) despite its relatively high EC50 
for activation of G551D-CFTR (236 nM VX-770) in primary HBE (24). In our studies, 
maximal reduction of ΔF508-CFTR PM density and function was seen at ~30 nM VX-770 
in CFBE. The effective in vivo intracellular concentration of VX-770, however, could be 
even higher than predicted due to the accumulation of VX-770 in primary HBE cells (56) 
and its eightfold enrichment in the epithelial lining fluid of the rat lung relative to plasma 
(59).
Because CFTR-mediated transepithelial transport is closely correlated with CF disease 
severity (23, 25, 60), evaluation of sustained exposure to modulators should be valuable in 
identifying individuals who would benefit from corrector-potentiator combination therapy 
with, for example, patient-derived primary or conditionally reprogrammed respiratory cells 
(61), or intestinal organoids (62). As a complementary strategy, new potentiators might be 
identified that lack the ΔF508-CFTR destabilizing action, as exemplified by the P5 (63). P5 
efficiently stimulated the activity of phosphorylated rΔF508-CFTR, but not G551D (63). 
The latter suggests that the mechanism of action of P5 is distinct from that of VX-770 and 
therefore could be valuable to correct the gating defect of ΔF508-CFTR while preserving its 
PM density.
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In summary, our results suggest that VX-770, as well as most of the available investigational 
potentiators, impairs the biochemical stability of ΔF508-CFTR and other class II processing 
mutations (such as P67L and R170G). These findings in cell cultures may translate to 
reduced efficacy of corrector-potentiator combination therapy in the clinical setting. Further 
structure-activity studies of existing potentiators, as well as identification of potentiators that 
do not destabilize mutant CFTRs, are warranted to enhance the therapeutic benefit of 
corrector-potentiator combination therapy in CF.
MATERIALS AND METHODS
Study design
The goal of the study was to measure the effect of long-term administration of VX-770 and 
other investigational potentiators, either alone or in combination with small-molecule 
correctors, on the biochemical and functional expression of ΔF508-CFTR in immortalized 
and primary human respiratory epithelia. CFBE heterologously expressing wild-type, 
G551D-, or ΔF508-CFTR and primary HBE with a CFTRWT/WT (from four donors) or a 
CFTRΔF508/ΔF508 (from six patients) genotype were subjected to chronic treatment with 
VX-770 (24 hours) in the presence or absence of the correctors VX-809 or VX-661, and 
CFTR function was determined by short-circuit current measurement or halide-sensitive 
YFP fluorescence quenching. The PM density, PM stability, cellular expression, 
conformational maturation, metabolic stability, and lysosomal targeting of ΔF508-CFTR 
were determined in CFBE to examine the cellular phenotype of the VX-770 destabilizing 
action. To elucidate the molecular mechanism of the VX-770 effect, we examined the 
functional destabilization of the mutant in a planar lipid bilayer and investigated the PM 
density and function of ΔF508-CFTR containing second-site mutations. Putative binding 
sites of potentiators were identified by molecular dynamic simulation and in silico docking. 
Finally, to assess the VX-770 effect specificity, the PM density and function of other class 
III and class II mutations (R347H-, R170G-, and P67L-CFTR) were determined in CFBE.
Antibodies and reagents
Mouse monoclonal anti–hemagglutinin (HA) anitbody was purchased from Covance 
Innovative Antibodies. VX-770, VX-809, and VX-661 were acquired from Selleckchem. 
The CFTR potentiators P1 to P10 were made available by R. J. Bridges (Rosalind Franklin 
University of Medicine and Science) and CFFT. All other chemicals were purchased from 
Sigma-Aldrich at the highest grade available.
Cell lines
Full-length human CFTR variants with the 3HA-tag in the fourth extracellular loop have 
been described before (10). The HRP-C was introduced into the fourth extracellular loop 
replacing the 3HA-tag by using the Eco RV/Avr II restriction sites with a 5′ linker 
(ctcgaatcaggaggtagtggtggcggaagt). The CFTR variants used in this study are listed in table 
S2. Maintenance of the human CF bronchial epithelial cell line CFBE41o− (32), with a 
CFTRΔF508/ΔF508 genotype [a gift from D. Gruenert, University of California, San Francisco 
(UCSF)], and stable cell line generation of CFTR-3HA variants under the control of a 
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tetracycline-responsive transactivator were described before (33). NCI-H441 and MDCK II 
cells expressing inducible ΔF508-CFTR have been described (10).
Primary HBE and short-circuit current measurements
Primary cultures of HBE cells from four CFTRΔF508/ΔF508 CF patients and four CFTRWT/WT 
donors were isolated and grown at ALI in ALI differentiation medium, as described (39, 64). 
Primary cultures differentiated in Ultorser G medium (38) from two CFTRΔF508/ΔF508 CF 
patients were purchased from ChanTest. Isc measurements of primary HBE and CFBE 
epithelia were performed as described (33, 65).
PM density measurement
The PM density of 3HA-tagged CFTR variants was determined by cell surface enzyme-
linked immunosorbent assay (ELISA) (6). HRP-tagged CFTR PM density was measured in 
a VICTOR Light Plate Reader (PerkinElmer) after addition of HRP-substrate (50 µl per 
well; SuperSignal West Pico, Thermo Fisher Scientific). PM density measurements were 
normalized with cell viability determined by alamarBlue Assay (Invitrogen).
Halide-sensitive YFP quenching assay
Assay of ΔF508-CFTR function by halide-sensitive YFP fluorescence quenching was 
performed as described (33). CFBE cells expressing inducible ΔF508-CFTR were 
transduced with lentiviral particles encoding the halide sensor YFP-F46L/H148Q/I152L (66) 
followed by isolation of double-expressing clones. YFP-expressing cells or controls were 
seeded onto 96-well microplates at a density of 2 × 104 cells per well, induced for ΔF508-
CFTR expression for 2 days at 37°C, and low temperature–rescued for an additional 48 
hours at 26°C. During the assay, cells were incubated in phosphate-buffered saline (PBS)–
chloride (50 µl per well) (140 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM 
KH2PO4, 1.1 mM MgCl2, 0.7 mM CaCl2, and 5 mM glucose, pH 7.4) containing the 
indicated potentiator concentrations, followed by well-wise injection of activator solution 
(50 µl per well) [20 µM forskolin, 0.5 mM 3-isobutyl-1-methyl-xanthine (IBMX), 0.5 mM 
8-(4-chlorophenylthio)-adenosine-3′,5′-cyclic monophosphate (cpt-cAMP)] and 100 µl of 
PBS-iodide, in which NaCl was replaced with NaI. The fluorescence was monitored for 36 s 
with a 5-Hz acquisition rate at 485-nm excitation and 520-nm emission wavelengths using a 
POLARstar OPTIMA (BMG LABTECH) fluorescence plate reader. After background 
subtraction and normalization to YFP signals before NaI injection, the I− influx rate was 
calculated by linear fitting to the initial slope.
Pulse-chase labeling
Experiments were performed as described (11). Briefly, CFBE cells expressing ΔF508-
CFTR were pretreated with 3 µM VX-809 for 24 hours followed by 1-hour exposure to 1 or 
0.1 µM VX-770. CFBE cells expressing ΔF508-CFTR-3S were exposed to 1 µM VX-770 
for 1 hour. CFTR variants were pulse-labeled with [35S]methionine and [35S]cysteine (0.2 
mCi/ml) (EasyTag EXPRESS Protein Labeling Mix, PerkinElmer) in cysteine- and 
methionine-free medium for 30 min and chased in full medium for 2.5 or 4.5 hours at 37°C 
in the presence of the indicated compounds. Radioactivity incorporated into the core- and 
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complex-glycosylated CFTR was visualized by fluorography and quantified by 
phosphorimage analysis with a Typhoon imaging platform (GE Healthcare).
Fluorescence ratiometric image analysis
The methodology for FRIA of endocytic vesicles containing CFTR as a cargo has been 
described in detail (43). Briefly, filter-grown CFBEi-ΔF508-3HA was allowed to polarize 
for 5 days and temperature-rescued for 48 hours at 30°C. VX-809 or VX-809 (3 µM) with 
0.1 µM VX-770 was added for the last 24 hours and kept during the experiment. Before 
labeling, the cells were shifted to 37°C for 1.5 hours. Subsequently, rΔF508-CFTR-3HA 
was labeled with anti-HA antibody and FITC-conjugated goat anti-mouse secondary Fab 
(Jackson ImmunoResearch) on ice. Synchronized internalization was performed at the 
indicated times at 37°C. FRIA was performed on a Zeiss AxioObserver Z1 inverted 
fluorescence microscope (Carl Zeiss MicroImaging) equipped with an X-Cite 120Q 
fluorescence illumination system (Lumen Dynamics Group Inc.) and Evolve 512 EMCCD 
(electron-multiplying charge-coupled device) camera (Photometrics Technology). The 
acquisition was carried out at 495 ± 5–nm and 440 ± 10–nm excitation wavelengths with a 
535 ± 25–nm emission filter and analyzed with MetaFluor software (Molecular Devices).
Planar lipid bilayer studies
Isolated CFTR-containing microsomes (containing 20 to 40 µg of total protein) were fused 
to planar lipid bilayers, and currents were analyzed as described previously (10, 11). Briefly, 
voltage was clamped at −60 mV, and currents were measured with a BC-535 amplifier 
(Warner Instrument) and pCLAMP 9 or 10 software (Axon Instruments), filtered at 200 Hz, 
and sampled at 10 kHz with an eight-pole Bessel filter and Digidata 1320 or 1440 digitizer 
(Axon Instruments). The chamber was gradually warmed from 23 to 37°C, reaching the 
maximum temperature within 8 to 9 min. Open probability (Po) values were calculated for 
2°C temperature intervals between 23 and 37°C, and the midpoints are depicted on the x 
axis.
Statistical analysis
Results are presented as means ± SEM, with the number of experiments indicated. Statistical 
analysis was performed by two-tailed Student’s t test with the means of at least three 
independent experiments. The 95% confidence level was considered significant. For Isc 
measurements, we performed paired t test analysis of patient/donor cells measured under 
different conditions. We used the Hill equation to calculate IC50 values in the GraphPad 
Prism software package. Original data and exact P values are provided in table S3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Prolonged VX-770 exposure reduces the PM expression of ΔF508-CFTR but not wild-type 
(WT) or G551D-CFTR in human CFBE
(A and C) PM density of ΔF508-CFTR-HRP (ΔF508) (A), G551D-CFTR-3HA (G551D) 
(A), and WT-CFTR-3HA (C). Cells were treated with VX-770 for 24 hours in the presence 
or absence of 3 µM VX-809 at 37°C, and the values are expressed as percentage of non–
VX-770-treated controls (n = 3). (B and D) PM density of low temperature (48 hours, 
26°C)–rescued ΔF508-CFTR-HRP (rΔF508-HRP) (B) or ΔF508-CFTR-3HA (rΔF508-3HA) 
(D). Cells were treated with VX-770 in the presence or absence of VX-809 (3 µM), BPO-27 
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(25 µM), or forskolin (1 µM) for 24 hours at 26°C followed by a 1-hour chase at 37°C (n = 
3). (E to G) Effect of VX-770 on the expression pattern of low temperature–rescued ΔF508-
CFTR-3HA determined by immunoblot. Cells were treated with VX-770 alone (E) or in 
combination with VX-809 (3 µM) (F) or VX-661 (3 µM) (G) for 24 hours at 26°C. CFTR 
was visualized with anti-HA antibody, and anti–Na+/K+-ATPase antibody served as loading 
control. Densitometric analysis of the core-glycosylated (B-band, filled arrowhead) or 
complex-glycosylated (C-band, empty arrow-head) ΔF508-CFTR is expressed as percentage 
of control (lower panels, n = 3 to 4). (H) Effect of VX-770 on WT- and G551D-CFTR 
expression measured by immunoblot (left panel) and quantification of the C-band density 
(right panel, n = 3). Error bars indicate SEM of three or four independent experiments.
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Fig. 2. Prolonged incubation with VX-770 reduces the maximal CFTR-mediated anion current in 
CFBE and primary cultures of ΔF508-CFTR but not WT-CFTR HBE
(A and B) Representative Isc recordings (A) and quantification of the changes in Isc (n = 3) 
(B) in CFBE monolayer expressing ΔF508-CFTR with or without 24-hour VX-770 (100 
nM), VX-809 (3 µM), or VX-661 (3 µM) pretreatment. CFTR-mediated currents were 
induced by sequential acute addition of VX-770 (770, 10 µM) and forskolin (frk, 20 µM) 
followed by CFTR inhibition with Inh172 (172, 20 µM) in the presence of a basolateral-to-
apical chloride gradient after basolateral permeabilization with amphotericin B. (C to E) 
Representative Isc traces (upper panels) and quantification of the Inh172 inhibited current 
(ΔIsc Inh172, lower panels) in HBE isolated from six different homozygous ΔF508 CF 
patients (C and D) or four WT-CFTR donors (E) with or without VX-770 treatment (24 
hours, 100 nM) alone (E) or in combination with VX-809 (3 µM) (C) and VX-661 (3 µM) 
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(D). The HBE cells were either polarized in Ultroser G medium (i) followed by 
measurement in the presence of a basolateral-to-apical chloride gradient and basolateral 
permeabilization with amphotericin B, or polarized in ALI medium (ii) and measured as an 
intact monolayer with equimolar chloride concentrations in both chambers. Error bars 
indicate SEM of three independent experiments (B) or SD of triplicate measurements (C to 
E). *P < 0.05, ***P < 0.001 (exact P values are listed in table S3).
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Fig. 3. Prolonged treatment with most potentiators reduces the PM density of rescued ΔF508-
CFTR
(A to H) Effect of potentiators P1 (A), P2 (B), P3 (C), P4 (D), P5 (E), P6 (F), P7 (G), and P8 
(H) on rΔF508-CFTR PM density in the presence or absence of 3 µM VX-809 (24-hour 
exposure, 26°C + 1-hour chase at 37°C, left axis, blue and red circles, n = 3) and function 
(acute addition, 32°C, right axis, gray circles, n = 3) in CFBE cells. (I and J) Representative 
Isc recordings (I) and quantification of the changes in Isc (n = 3) (J) in CFBE monolayer 
expressing rΔF508 with or without 24-hour P6 (genistein, 10 to 100 µM) pretreatment. 
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CFTR was activated by sequential acute addition of forskolin (20 µM) and genistein (10 to 
100 µM) followed by CFTR inhibition with Inh172 (20 µM) in the presence of a basolateral-
to-apical chloride gradient after basolateral permeabilization with amphotericin B. Error bars 
indicate SEM of three independent experiments.
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Fig. 4. Prolonged exposure to potentiator P5 does not impair the expression and function of 
ΔF508-CFTR
(A) Effect of P5 on the expression pattern of rΔF508, determined by immunoblot. Cells 
were treated with P5 in combination with VX-809, and CFTR was visualized using anti-HA 
antibody. Anti–Na+/K+-ATPase antibody served as loading control. Densitometric analysis 
of the core-glycosylated (B-band, filled arrowhead) or complex-glycosylated (C-band, 
empty arrowhead) rΔF508 is expressed as percentage of non–P5-treated controls (right 
panel, n = 3). (B) Representative Isc recordings (left panel) and quantification of the changes 
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in Isc (n = 3, right panel) in CFBE monolayer expressing ΔF508-CFTR with or without 24-
hour P5 (3 µM) pretreatment. Measurements were performed in the presence of a 
basolateral-to-apical chloride gradient after basolateral permeabilization. (C) Representative 
Isc traces (left panel) and quantification of the Inh172 inhibited current (ΔIsc Inh172, right 
panel) in HBE isolated from four different homozygous ΔF508 CF patients with or without 
P5 treatment (3 µM, 24 hours, 37°C) in combination with VX-809 (3 µM). The HBE cells 
were polarized in ALI medium and measured without permeabilization with symmetrical 
chloride-containing solutions. Error bars indicate SEM of three independent experiments (A 
and B) or SD of triplicate measurements (C).
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Fig. 5. VX-770 attenuates the maturation and accelerates the PM removal of ΔF508-CFTR
(A) Determination of ER folding efficiency of ΔF508-CFTR in the presence of VX-809 (3 
µM, 24 hours, left panel, n = 5) or of ΔF508-3S in the absence of VX-809 (right panel, n = 
3) by metabolic pulse-chase in CFBE cells with or without VX-770 (1.0 or 0.1 µM, 1-hour 
pretreatment). The folding efficiency was calculated as the percentage of pulse-labeled, 
immature core-glycosylated ΔF508-CFTR (B-band, filled arrowhead) conversion into the 
mature complex-glycosylated form (C-band, open arrowhead). Labeling was performed for 
30 min followed by chase for 2.5 hours at 37°C. (B and C) Effect of VX-770 on the PM 
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stability of low temperature– rescued (48 hours, 26°C) ΔF508-CFTR (rΔF508). CFBE 
monolayer was treated with VX-770 (1 µM, 3 or 24 hours, 26°C) alone (B) or in 
combination with VX-809 (3 µM) (C) followed by chase at 37°C for 1.5 or 3 hours (n = 4). 
(D) Stability of rΔF508 in CFBE cells treated with VX-770 (100 nM, 24 hours) and VX-809 
(3 µM, 24 hours) was determined by immunoblot with CHX chase. (E) Complex-
glycosylated CFTR [open arrowhead in (D)] disappearance was quantified by densitometry 
and is expressed as percentage of initial amount (n = 3). (F) Effect of each potentiator (P1, 
P4, P7, and P8, 30 µM; P2 and P3, 3 µM; P5, 10 µM; and P6, 100 µM; 24 hours, 26°C) on 
the PM stability of rΔF508 (n = 3). (G) Representative histogram of rΔF508-containing 
vesicular pH measured by FRIA. The cells were treated with dimethyl sulfoxide (DMSO), 
VX-809 (3 µM), or VX-809 and 0.1 µM VX-770 for 24 hours and during the 120-min chase. 
The Gaussian distribution of the vesicular pH of 280 vesicles is indicated for each condition. 
(H) Influence of VX-770 on the endolysosomal transfer kinetics of rΔF508. The graph 
shows the mean vesicular pH at each chase point (n = 3). Error bars indicate SEM of three to 
five independent experiments. *P < 0.05, **P < 0.01 (exact P values are listed in table S3).
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Fig. 6. VX-770 directly interacts with and destabilizes the ΔF508-CFTR-2RK channel
(A) Representative records show ΔF508-R29K-R555K-CFTR (ΔF-2RK) channel function in 
the presence of 1 µM VX-770 from two separate experiments at ~25°C (two channels 
incorporated), ~30°C, and ~35°C (one channel incorporated). The closed (c) and open (o) 
states of the channels are indicated. (B) Single-channel open probabilities (Po) of protein 
kinase A–activated ΔF508-CFTR-2RK in the presence or absence of VX-770 (1 µM) (n = 7 
to 46). The cumulative duration of single-channel measurements for any given temperature 
exceeded 8.5 min. (C) Temperature-dependent inactivation of ΔF508-2RK in the presence 
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or absence of VX-770 (1 µM) derived by normalization with 24°C values of the results 
depicted in (B). (D and E) Single-channel open probabilities (Po) of protein kinase A–
activated ΔF508-CFTR-R1S (ΔF508-R1S, n = 4 to 13) (D) or ΔF508-CFTR-E1371S (ΔF-
E1371S, n = 4 to 6) (E) determined by artificial phospholipid bilayer measurements in the 
presence or absence of VX-770 [1 µM in (D), 0.1 µM in (E)]. The cumulative measurement 
time for any given temperature was >4.5 min for ΔF508-R1S and >3 min for ΔF508-
E1371S. Error bars indicate SEM of 4 to 46 independent experiments. *P < 0.05, **P < 0.01 
(exact P values are listed in table S3).
Veit et al. Page 30
Sci Transl Med. Author manuscript; available in PMC 2015 July 23.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 7. Suppressor mutations of ΔF508-CFTR and other CF-causing CFTR mutations modulate 
the susceptibility to VX-770– mediated PM down-regulation
(A) PM density of ΔF508-CFTR with or without second-site suppressor mutations and of 
non–ΔF508-CFTR variants was measured after VX-770 (100 nM, 24 hours) incubation (n = 
3). (B and D) PM density of ΔF508-3S (B) (n = 3) and ΔF508-R1S (D) (n = 3) after 24 
hours of treatment with increasing concentrations of VX-770 in the presence or absence of 
VX-809 (3 µM). (C) 50% inhibitory concentration (IC50) of VX-770 on CFTR variants’ PM 
expression, calculated on the basis of the measurements shown in (B), (D), and fig. S5 (B to 
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F). (E and F) PM density of R347H-CFTR (E) and R170G-CFTR (F) after 24 hours of 
treatment with increasing concentrations of VX-770 in the presence of DMSO or VX-809 (3 
µM). (G) CFTR PM density after VX-770 (100 nM, 24 hours) incubation, measured for CF-
causing mutants G551D-, R347H-, R170G-, and P67L-CFTR (n = 3). The values for ΔF508- 
and WT-CFTR are shown for comparison. (H) Quantification of the changes in Isc (n = 3) 
(B) in CFBE monolayers expressing R347H-, R170G-, or P67L-CFTR with or without 24-
hour VX-770 (100 nM) and VX-809 (3 µM) pretreatment (n = 3 to 4). Error bars indicate 
SEM of three to four independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (exact 
P values are listed in table S3).
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